DEBIOPHARM FURTHER EXPLORES THE POTENTIAL OF ITS POTENT, HIGHLY SELECTIVE WEE1 INHIBITOR DEBIO 0123 IN PHASE 1 CANCER STUDY
Lausanne, Switzerland (ots) - Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly ...